Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 314

Results For "ED"

9532 News Found

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder
Drug Approval | December 18, 2025

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder

The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India


FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Drug Approval | December 18, 2025

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis


Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board
People | December 17, 2025

Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board

Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute


Lupin receives EIR from USFDA for Nagpur injectable facility
Drug Approval | December 17, 2025

Lupin receives EIR from USFDA for Nagpur injectable facility

The EIR was issued following an inspection of the facility from September 8 to September 16, 2025


Cynata completes patient enrollment for Phase 2 aGvHD clinical trial
Clinical Trials | December 17, 2025

Cynata completes patient enrollment for Phase 2 aGvHD clinical trial

Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease


Gujarat Kidney and Super Speciality to file IPO at Rs.108- Rs.114 per share
News | December 17, 2025

Gujarat Kidney and Super Speciality to file IPO at Rs.108- Rs.114 per share

The company operates a chain of mid-sized multi-speciality hospitals


Minghui Pharmaceutical gets FDA green light for Phase III trials of its therapy in thyroid eye disease
Clinical Trials | December 17, 2025

Minghui Pharmaceutical gets FDA green light for Phase III trials of its therapy in thyroid eye disease

The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies


Ascletis Pharma reports positive Phase I results for oral IL-17 inhibitor
Clinical Trials | December 17, 2025

Ascletis Pharma reports positive Phase I results for oral IL-17 inhibitor

The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants


Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma
News | December 17, 2025

Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma

Hansoh Pharma will receive an upfront payment in the low double-digit millions